chrisvoncsefalvay/vaers-outcomes huggingface dataset:
joint swelling in the second finger of left hand; pain in the second finger of left hand; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 73-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration, administered in Arm Left on 06Feb2021 16:00 (at the age of 73 years), (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation at clinic. Medical history included high blood pressure from an unknown date and unknown if ongoing. Concomitant medications included amlodipine taken for blood pressure abnormal from an unspecified start date and ongoing; lisinopril taken for blood pressure abnormal from an unspecified start date and ongoing. On 11Feb2021 the patient experienced joint swelling in the second finger of left hand, pain in the second finger of left hand. The events resulted in visit to Physician Office. The clinical outcome of the events joint swelling in the second finger of left hand was recovering, pain in the second finger of left hand was not recovered at the time of report.  Follow-up attempts completed. No further information expected.
Sore, itching, redness, lump swelling, headache joint/muscle aches.
became faint; severe thirst; fatigue; loss of balance; This case was reported by a nurse via sales rep and described the occurrence of faint in a male patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On an unknown date, 5 min after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced faint (serious criteria GSK medically significant), thirst, fatigue and loss of balance. On an unknown date, the outcome of the faint, thirst, fatigue and loss of balance were unknown.   It was unknown if the reporter considered the faint, thirst, fatigue and loss of balance to be related to Bexsero and Bexsero Pre-Filled Syringe Device.  This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported. The patient was requested to wait 15 minutes after administration of Bexsero vaccine. The patient waited 5 minutes, entered waiting area of clinic and became faint and additionally had severe thirst, fatigue, loss of balance. The patient was returned to room where kept for 30 minutes minutes. The reporter consented to follow up.
leg pain; flu like symptoms; headache; A spontaneous report reported by a consumer concerning a female patient of unknown age who received Moderna's COVID vaccine and experienced the events leg pain , headache and flu-like symptoms.  The patient's medical history was not provided .Concomitant medications were not reported.  On 15 Feb 2021 , prior to the onset of the event, the patient received first of two planned doses of   mRNA-1273 (batch number-unknown)  via unknown route of administration for prophylaxis of COVID 19 infection.  On an unknown date, the patient experienced event like leg pain, headache and flu -like symptoms.   No treatment medications were reported.  Action taken with mRNA-1273 in response to event was unknown.  Outcome of the events  like leg pain, headache and flu -like symptoms were considered to be unknown.
Child was vaccinated with expired vaccine, I was instructed by Department to fill out VEARS report. Child did not have any adverse reaction and did not need treatment.
0900 PT arrived on site, expressed that she had a recent mild reaction to PEG during a recent colonoscopy.  States that she broke out with hives on her face and arms.    PT was administered 0.5ml of benedryl prior to administration of vaccination and had her wait 10 min for medicine to take effect.    0913 PT was administered 0.3ml of Pfizer COVID vaccine. 0922 PT's started to show signs of distress with heavy breathing.  Upon first contact with PT she was speaking with labored breathing.  0924 PT started to seize.  Dr. attempted to communicate with PT and reclined her car seat gain better access.   0925 EMS was called 0925 Epi Pen was administered (successfully) PT started to communicated again but started to feel light headed and nauseous and was returned to a sitting position.  RN had taken over and was assisting with PT care. 0938 Paramedics arrived on scene  1005 Paramedics cleared scene and transported PT to ER.
Swelling, pain, redness, skin hot to touch onset 10/25/2006 then present (alternate warm and cold compress and Motrin).
Information has been received from a nurse concerning a female who on an unspecified date was vaccinated with GARDASIL vaccine (yeast) (Lot #, site, route and dose # not reported). On an unspecified date, the patient had "warts on her hands" after getting GARDASIL vaccine (yeast). The patient sought unspecified medical attention by calling the nurse. The patient outcome was not reported. No additional information was reported. Additional information has been requested.
pt vaxed 20NOV95 & devel papules on face ? post hep rash; no treatment;seen in clinic on 24NOV95
This case was reported by a physician and described the occurrence of hepatitis B core antigen positive in a 3-year-old male subject who was vaccinated with PEDIARIX (GlaxoSmithKline) for prophylaxis. Concurrent vaccination included Haemophilius influenzae type b vaccine (Merck) and PREVNAR (Wyeth) given on 31 August 2004. On 31 August 2004 the subject received 3rd dose of Pediarix at 0.5 ml in the right thigh. On 18 May 2007, 3 years after vaccination with Pediarix, the subject experienced hepatitis B core antigen positive and hepatitis B surface antigen negative. At the time of reporting the outcome of the events was unspecified.
I am not feeling well at all, this is hard for me even to reach out for help right now; I don''t feel well, I don''t feel good; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (COMIRNATY), administration date 06Jan2022 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Manufacturer: Unknown, Dose number: 1), for Covid-19 immunization. The following information was reported: MALAISE (non-serious) with onset 06Jan2022, outcome "unknown", described as "I am not feeling well at all, this is hard for me even to reach out for help right now; I don''t feel well, I don''t feel good".  Additional information: Consumer stated, "I am trying to figure out if I need to go to the ER, I got my second COVID shot today its a Pfizer shot, I am not feeling well at all and I never get sick. So this is hard for me even to reach out for help right now." Consumer was suggested to contact the nearest Pharmacy or Clinic in case of emergency.   No follow-up attempts are completed. No further information is expected.
A 56 year old male with unknown medical history who denies any allergies, received a 2nd dose of Anthrax vaccine on 18 December 1999. It is unknown if any other vaccines were given on this date. The patient was taking Calan at the time of the event. It is also unknown if the patient had any illness at the time of the vaccination or a history of reactions to previous vaccinations. On an unknown date after the second Anthrax vaccination, the patient developed a poison ivy-like rash over the torso, groin and upper arms that was mildly pruritic. The patient denies any constitutional symptoms. During an examination on 17 January 2000, the rash was described as flat, lichenified with irregulary shaped plaques of approximately 10 mm x 5 mm, An area of induration was noted in the distal right deltoid at the injection site. Additionally, the patient had non tender areas of scabbing with secondary pruritus. The patient applied alcohol to the rash for relief. After examination, the physician suggested using Solarcaine instead of alcohol. On 06 March 2002, the patient was seen by a dermatologist and reported he had a three month history of pruritic patches involving his trunk and extremities. He also reported treated with Gold Bond anti-itch cream which resulted in little improvement. Upon exam, multiple erythematous patches involving the patient's trunk and extremities were described. Some lesions had an annular configuration with a slight raised border, a few vesicles were present on the soles of the patient's feet. A biopsy was taken from a representative lesion on the patient's right arm. The patient was treated wtih Triamcinolone ointment applied once to twice daily to the pruritic patches. On 09 March 2000, the biopsy report returned the diagnosis of pityriasis rosea. On 31 March 2000, at a follow up visit to the dermatologist, the patient stated the rash on his body was clearing somewhat, but occasionally flares on his back. It was recommended that the patient continue using 0.1% Triamcinolone ointment once daily for a few weeks. At the time of this report, the patient's recovery status was unknown.
This spontaneous report was received from a physician via a company representative concerning a patient of unknown age and gender. On an unknown date (reported as a few years ago), the patient was vaccinated with a dose of ZOSTAVAX (dose, route and lot number unspecified). No concomitant medications were reported. On an unknown date, the patient experienced a mild case of shingles. The outcome of shingles was unknown. The relatedness for shingles was unknown for ZOSTAVAX. It was unknown if the patient had sought medical attention. Additional information is not expected.
I?ve been spotting before getting my period for the last eight months. I spotted two days before I got my period in May,  1 day before in June,  two days before in July, two days before in August, one week before in October, and one day before in November. The spotting lasted anywhere from 1 to 3 days. September and December were the only months where I didn?t spot. Nothing has changed in my diet, exercise, or medication routine. I have never spotted before in my life
PMR; cyanosis of palm of hand; severe pain in shoulders and hips; bad headache; fever; myalgia; extreme discomfort; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of POLYMYALGIA RHEUMATICA (PMR) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032M20A and 015M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Mar-2021, the patient experienced MYALGIA (myalgia), DISCOMFORT (extreme discomfort), HEADACHE (bad headache) and PYREXIA (fever). On 22-Mar-2021, the patient experienced CYANOSIS (cyanosis of palm of hand) and ARTHRALGIA (severe pain in shoulders and hips). On 29-Mar-2021, the patient experienced POLYMYALGIA RHEUMATICA (PMR) (seriousness criterion medically significant). At the time of the report, POLYMYALGIA RHEUMATICA (PMR), MYALGIA (myalgia), DISCOMFORT (extreme discomfort), CYANOSIS (cyanosis of palm of hand), ARTHRALGIA (severe pain in shoulders and hips), HEADACHE (bad headache) and PYREXIA (fever) outcome was unknown.            Action taken with mRNA-1273 in response to the events was not Applicable. Concomitant information not provided  Additional and treatment information:On 22MAR2021 cyanosis of palm of hand and severe pain in shoulders and hips which has decrease her ability to perform some of her daily living activities because of the pain. On 29MAR2021 she went to urgent care and was verbally diagnosed with PMR. She stated that the HCP told her it was PMR from the 2nd dose of vaccine but the paperwork stated it was musculoskeletal pain. She was started on a Medrol dosepak and referred to her general practitioner. She saw her GP on 6PAR2021 that confirmed the diagnosis of PMR and prescribed her prednisone. On 13APR2021 she was told to half her prednisone dose and almost all the symptoms are returning. She has a fear of no remission.   This case was linked to MOD-2021-076703 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Fatigue; muscle soreness; Tightness in chest; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 23Apr2021 at 08:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient did not receive any medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration on 02Apr2021 at 09:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On an unknown date in Apr2021, since second injection, the patient experienced fatigue, muscle soreness and tightness in chest. The adverse events did not result in doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, muscle soreness and tightness in chest were unknown at the time of this report.    No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt was vaccinated on Oct 25, 2007 with Zostavax. He presented today with possible dermatolmal zoster
A non-serious spontaneous report of inadvertently administered expired FLUMIST was received from a health professional concerning a ten-year-old patient. Neither relevant medical history nor concomitant medications have been reported for this patient. The vaccine expired on 06-Dec-2010. The patient received the expired FLUMIST on 23-Dec-2010. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved.
Headache, Arthralgia, NauseaVomiting, chills, fatigue, acid reflux, brain fog, swelling at injection site Narrative:
Heart Attack 3 hours after receiving the 2nd Moderna vaccination for C19. Pacemaker went off at least 5-6 times causing more damage to an already 20% functioning heart.kk
Underdose; Engerix-B pediatric dose to adult; This non-serious case was reported by a nurse via call center representative and described the occurrence of underdose in a 22-year-old female patient who received HBV (Engerix B pediatric) (batch number FB9RH, expiry date 21-JAN-2024) for prophylaxis.   On 22-JUN-2023, the patient received Engerix B pediatric. On 22-JUN-2023, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Underdose) and adult use of a child product (Verbatim: Engerix-B pediatric dose to adult). The outcome of the underdose and adult use of a child product were unknown.   Additional Information: GSK receipt date: 24-Jul-2023 The nurse called to report a pediatric dose of Engerix B was administered to an adult patient which led to underdose and adult use of a child product. The reporter consented to follow up via email.
This case was reported by a pharmacist via call center representative and described the occurrence of fever in a 51-year-old female patient who received SHINGRIX (batch number 3Z53C, expiry date 13th March 2021) for prophylaxis. On 7th December 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced fever, chills and malaise. On 11th December 2018, the outcome of the fever, chills and malaise were recovered/resolved. It was unknown if the reporter considered the fever, chills and malaise to be related to SHINGRIX. Additional details were provided as follows: The patient developed fever, chills and malaise. All the symptoms had resolved by the morning on the date of reporting. No further details were reported regarding the event. The reporter gave consent to follow up.
31AUG92 pt spiked t103 & c/o h/a & sore neck; was taken to hosp & treated w/PCN & phenergan & sent home; 1SEP92 pt had seizure & was taken to hosp adm to hosp 1SEP92; pt has been in coma since 1SEP92;
Headache, weak feeling in legs and thick fuzzy mouth - sense of taste weird on the next day (10/25) Then on 10/26 and 10/27 mouth felt numb and lips a skewed on the right side. 10/28/2017 right eye drooped, can't blink and wouldn't close all the way. ER room diagnosed on 10/28/2017 as Bell's Palsy. I had Bell's Palsy 35 years ago. It presented as immediate one side facial paralysis. This has been a progressive loss of function.
Following day - incapacitated, to dizzy to get off floor, extreme diarrheal, some nausea, chills.  Symptoms passed without medical assistance by mid morning the next day.
Patient tested positive on 02/16/2022 at hospital.  Patient admitted same day with chills, cough, abdominal pain.  No release date given with charting in database. Hospital days stay unknown. Patient has underlying health conditions.
4 year old patient received Kinrix (DTaP & IPV) and Proquad (MMR & varicella).  Patient returned with mother and father to clinic after vomiting about 30 minutes after receiving shots. Was also very pale and lethargic. Patient stated to mother that her throat was hurting. Taken to ER immediately.
he was literally hit with the sensation that his back got thrown out/ His back and liver area is hurting.; I didn't lift anything, I didn't do any new activity./ it almost dropped me to my knees; His back and liver area is hurting.; back pain; This is a spontaneous report from a contactable consumer (patient himself). A 38-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection; Lot number and expiry date were not reported) via an unspecified route of administration on 09Jul2021 as a dose 2, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received first dose of BNT162B2 (COVID Pfizer vaccine) on an unspecified date for COVID-19 immunization. On 10Jul2021 he was literally hit with the sensation that his back got thrown out. On an unspecified date in Jul2021, his back and liver area was hurting. It came out of nowhere, I didn't lift anything, I didn't do any new activity. Then Saturday he was hit with literally the sensation that his back got thrown out. He was a healthy person. He does not even take Tylenol. He unfortunately was forced to take the covid vaccine. He was asking has anyone else reported this. His back and liver area was hurting. He thought that it would pass. It gets better, and here today it came back. Patient's concern was it returned again today, he was helping his 03-year-old son put on his seat belt when it hit him like it did on Saturday, it almost dropped him to my knees and guess his concern was that resurfaced fairly quickly and it never dissipated completely but it hit him like it did Saturday at work. The outcome of the event movements reduced was unknown and for all other events was not resolved.  Information on batch/lot number has been requested.
Pt developed pain and hives around injection site. Redness less than 4 inches by 1 inch. Pain 10/10. Erroneously given.
Red, swollen and warm to touch at injection site she received on 9/26/18 and came to RX w/cc on 9/28/18 at 8:00 am. Pt went to PT 1st as instructed by RPh and was given triamcinolone cream and doxycycline 100 mg caps.
Pt felt lightheaded and dizzy several minutes after receiving the vaccine.  She sat down for a few minutes, blood pressure was 114/92. She was given a cold bottle of water. After a few minutes, she felt better . Her blood pressure was normal -124/80.  She was able to walk out with no adverse feelings.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 46-year-old male patient received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: Tested negative then positive again; Positive, notes: Tested negative then positive again. Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sick for weeks; Initial information was received on 07-Oct-2020 regarding an unsolicited valid non-serious case from a consumer/non-health care professional.  This case involves patient (gender unspecified) who was sick for weeks (malaise), while received vaccine INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient was sick for weeks (malaise) (unknown latency, non-serious event) following the administration of INFLUENZA VACCINE.  No laboratory data was provided   It was not reported if the patient received a corrective treatment.  At the time of report, the outcome of event was unknown.  There will be no information available on lot number.